An aluminum rotor mounted to the wheel saves weight, cuts noise, and doesn't rust.
NYS Entity Status
NYS Filing Date
JANUARY 02, 2014
NYS DOS ID#
ROY HARRY SAM
36-36 32ND STREET
ASTORIA, NEW YORK, 11106
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - DISCOUNT BRAKES & TIRES INC
Around the Web
- Continental rethinks the wheel—and the brake—for electric cars
By Jonathan M. Gitlin - Friday Aug 25, 2017
- Nearly 650,000 Jeep & Dodge SUVs Recalled Over Potentially Degraded Brakes
By Ashlee Kieler - Tuesday Oct 3, 2017
Fiat Chrysler recalled more than half a million SUVs this week because it can be dangerous when your brakes don’t work properly. FCA announced today the recall of 646,394 model year 2011 to 2014 Dodge Durango and Jeep Grand Cherokee vehicles after finding that the shield around the brake line could be compromised.The carmaker says that the shields designed …
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."
- Time Inc. Launches 'People Perks' Membership for Product Discounts
Wednesday Sep 27, 2017
Time Inc. is offering memberships for $60 per year or $5.99 per month that give consumers access to deals on products related to entertainment, beauty, food, pets and more. It’s part of wider efforts to develop new revenue sources.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.
- Biggest Cowboys fantasy problem isn’t even Ezekiel Elliott
By Drew Loftis - Tuesday Nov 14, 2017
Don’t you hate when you think you have one problem, attempt to solve it, only to find there is a larger problem that renders your previous solution moot? You know, like taking care to get your tires rotated, and finding out your brakes need to be fixed. Or running out of paper in the printer...